Prostate cancer (PC) is the most common cancer in men and the second leading cause of
cancer-related death worldwide. Many therapeutic advances over the last two decades have …

Osteosarcoma (OS) is the most common primary malignant bone tumour with a peak in
incidence during adolescence. Delayed patient presentation and diagnosis is common with …

Background Once castration resistance is documented and secondary hormone therapy is
ineffective, standard treatment of metastatic prostate cancer is docetaxel, with …

Purpose We previously demonstrated that thalidomide appears to add to the activity of
docetaxel in metastatic castration-resistant prostate cancer (CRPC). Phase II studies …

Background This study explored the efficacy and tolerability of sunitinib, an inhibitor of
tyrosine kinase receptors, in men with castration-resistant prostate cancer (CRPC). Methods …

Purpose. The adverse events associated with bevacizumab therapy are characterized, and
the underlying pathophysiology, risk factors, frequency, and management of these events …

Patients with castration‐resistant prostate cancer (CRPC), who progress after docetaxel
therapy, had until very recently, only a few therapeutic options. Recent advances in this field …

Solid tumors can be thought of as multicellular'organs' that consist of a variety of cells as well
as a scaffold of noncellular matrix. Stromal–epithelial crosstalk is integral to prostate cancer …

Until very recently, docetaxel was the only approved agent in castration-resistant prostate
cancer (CRPC) and other effective therapeutic options are urgently needed. In recent years …

Abstract Learning Objectives After completing this course, the reader will be able to:
Promptly recognize cardiovascular adverse events associated with anti-VEGF therapy in …